| Title: | Luminally expressed gastrointestinal biomarkers |
| Author(s): | Cummins G; Yung DE; Cox BF; Koulaouzidis A; Desmulliez MPY; Cochran S; |
| Address: | "a Institute of Sensors, Signals and Systems, School of Engineering and Physical Sciences , Heriot-Watt University , Edinburgh , UK. b The Royal Infirmary of Edinburgh , Endoscopy Unit , Edinburgh , UK. c School of Medicine , University of Dundee , Dundee , UK. d Medical and Industrial Ultrasonics, School of Engineering , University of Glasgow , Glasgow , UK" |
| Journal Title: | Expert Rev Gastroenterol Hepatol |
| DOI: | 10.1080/17474124.2017.1373017 |
| ISSN/ISBN: | 1747-4132 (Electronic) 1747-4124 (Linking) |
| Abstract: | "A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract. Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH. Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility" |
| Keywords: | "Biomarkers, Tumor/*metabolism Colorectal Neoplasms/*metabolism/therapy Humans Inflammation Mediators/*metabolism Inflammatory Bowel Diseases/*metabolism/therapy Intestinal Mucosa/*metabolism Predictive Value of Tests Prognosis Reproducibility of Results B;" |
| Notes: | "MedlineCummins, Gerard Yung, Diana E Cox, Ben F Koulaouzidis, Anastasios Desmulliez, Marc P Y Cochran, Sandy eng Review England 2017/08/30 Expert Rev Gastroenterol Hepatol. 2017 Dec; 11(12):1119-1134. doi: 10.1080/17474124.2017.1373017. Epub 2017 Sep 14" |
